新华社国际传播融合平台出品 责编：秦雅楠、王瑞景 记者：陈杰、唐斯琦、方喆 新华社音视频部制作 0:00 1月7日上午，韩国总统李在明在上海出席中韩创新创业论坛。近300名来自中韩两国智能制造、新材 料、人工智能、医疗健康、文化创意与消费服务等领域的企业代表出席论坛。本次活动旨在拓展中韩创 新企业合作渠道，推动中韩企业共同挖掘潜在商机，推动多领域开放式创新合作。 ...

0:00 1月7日上午，韩国总统李在明在上海出席中韩创新创业论坛。 编辑: 董智杰 责编: 刘佳 近300名来自中韩两国智能制造、新材料、人工智能、医疗健康、文化创意与消费服务等领域的企业代 表出席论坛。本次活动旨在拓展中韩创新企业合作渠道，推动中韩企业共同挖掘潜在商机，推动多领域 开放式创新合作。 会后，李在明参观了中国企业展示的各类高科技产品，并与其中一款机器人握手。 ...

访华第4天！韩国总统李在明与中国机器人握手 访华第4天！韩国总统李在明与中国机器人握手 #李在明被中国机器人一句话逗笑#【访华第4天！韩国总统李在明与中国机器人握手】#李在明在上海体 验VR开心大笑#1月7日上午，韩国总统李在明在上海出席中韩创新创业论坛。近300名来自中韩两国智 能制造、新材料、人工智能、医疗健康、文化创意与消费服务等领域的企业代表出席论坛。本次活动旨 在拓展中韩创新企业合作渠道，推动中韩企业共同挖掘潜在商机，推动多领域开放式创新合作。会后， 李在明参观了中国企业展示的各类高科技产品，并与其中一款机器人握手。 特别声明：以上文章内容仅代表作者本人观点，不代表新浪网观点或立场。如有关于作品内容、版权或其它问 题请于作品发表后的30日内与新浪网联系。 ...

Core Viewpoint - Open innovation collaboration is becoming a consensus among multinational pharmaceutical companies, which helps improve R&D efficiency [1][6] Group 1: R&D Investment and Strategy - Roche has significantly increased its R&D investment in China, establishing the Roche China Innovation Center and the Roche China Accelerator, which are key components of its early drug development ecosystem in China [1][4] - The Roche China Accelerator, launched in May 2021, has received nearly 300 million RMB in investment and aims to enhance collaboration with local biotech firms [4] - The Roche China Innovation Center, upgraded in 2019 with an additional investment of 863 million RMB, has successfully advanced 11 drug molecules into clinical trials [5] Group 2: Multinational Companies in Shanghai - Six of the top ten global pharmaceutical companies have established R&D centers or incubators in Shanghai, including Johnson & Johnson, Roche, Pfizer, AstraZeneca, Novartis, and Sanofi [2] - AstraZeneca has designated Shanghai as a global strategic center for R&D, commercial operations, and production, alongside its major centers in the UK and the US [5] Group 3: Collaborative Innovation - There is a growing trend of collaborative innovation between multinational pharmaceutical companies and local Chinese firms, moving away from isolated R&D efforts [2][12] - Roche has established nearly 15 early-stage R&D collaborations with member companies of the Roche China Accelerator [5] Group 4: Market Transactions and Acquisitions - Recent high-value licensing deals, such as the one between Shanghai-based Innovent Biologics and Pfizer, highlight the increasing interest of multinational companies in Chinese innovation [9] - The licensing agreement for the PD-1/VEGF dual antibody drug SSGJ-707 involved a record upfront payment of up to 1.25 billion USD, indicating the potential commercial value of Chinese-developed drugs [9] - The overall trend shows that multinational companies are actively acquiring innovative drug pipelines in China to fill gaps left by expiring patents [12] Group 5: Shanghai's Biopharmaceutical Ecosystem - Shanghai has become a leading hub for biopharmaceutical innovation, with a robust ecosystem supported by numerous research institutions, hospitals, and a large pool of talent [13][14] - The city has seen its biopharmaceutical industry grow from an industrial output of less than 5 billion RMB in 1993 to over 200 billion RMB today [13] - Government policies have played a crucial role in fostering a conducive environment for pharmaceutical R&D, including support for clinical trials and internationalization efforts [15][16]